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A multicentre parallel-group randomised
trial assessing multiparametric MRI
characterisation and image-guided biopsy
of prostate in men suspected of having
prostate cancer: MULTIPROS study protocol
Magdalena Szewczyk-Bieda1†, Cheng Wei2†, Katherine Coll3, Stephen Gandy4, Peter Donnan5,
Senthil Kumar Arcot Ragupathy6, Paras Singh7, Jennifer Wilson8 and Ghulam Nabi2*
Abstract
Background: There is growing evidence suggesting that multiparametric magnetic resonance imaging (mpMRI) is
a marker for prostate cancer (PCa) aggressiveness and could be used to plan treatment. Improving early detection
of clinically significant PCa with pre-biopsy mpMRI would very likely have advantages including optimising the
diagnosis and treatment of diseases and diminishing patient anxiety.
Methods and materials: This is a prospective multicentre study of pre-biopsy mpMRI diagnostic test accuracy
with subgroup randomisation at a 1:1 ratio with respect to transrectal ultrasound (TRUS) and MRI/US fusion-guided
biopsy or TRUS-only biopsy. It is designed as a single-gate study with a single set of inclusion criteria. The total
duration of the recruitment phase was 48 months; however, this has now been extended to 66 months. A sample
size of 600 participants is required.
Discussion: The primary objective is to determine whether mpMRI can improve PCa detection and characterisation.
The key secondary objective is to determine whether MRI/US fusion-guided biopsy can reduce the number of false-
negative biopsies. Ethical approval was obtained from the East of Scotland Research Ethics Committee 1 (14/ES/
1070) on 20 November 2014. The results of this study will be used for publication and presentation in national and
international journals and at scientific conferences.
Trial registration: ClinicalTrials.gov, NCT02745496. Retrospectively registered on 20 April 2016.
Keywords: Prostate cancer, Multiparametric magnetic resonance imaging, Prostate biopsy
Background
Introduction and rationale
Men suspected of having prostate cancer (PCa) because
of high levels of serum prostate-specific antigen (PSA)
and/or abnormal digital rectal examination (DRE) are of-
fered prostate biopsies guided by transrectal ultrasound
(TRUS). Several challenges are seen in this crucial step.
Firstly, the incidence of false-negative biopsies (i.e. clin-
ically significant tumours not being detected) may be as
high as 35% in first-time biopsies [1]; secondly, up to
44% of men younger than 70 years of age may need a
second set of biopsies following initial negative results
[2]; thirdly, up to 50% of PCa cases currently detected by
these methods may not be clinically relevant when con-
sidering other patient-related factors; fourthly, data from
UK Prostate Testing for Cancer and Treatment (Pro-
tecT) has shown significant morbidity of the biopsy pro-
cedure, at times even leading to patient death [3]; and,
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finally, several studies have shown no improvement in
PCa mortality, despite increased detection rates through
screening programmes [4], and the number of deaths
from PCa in the UK sadly remains largely unchanged.
Post-biopsy standard of care magnetic resonance im-
aging (MRI) is offered to patients with positive biopsy
results or when there is a continuous increase in PSA
levels despite negative biopsies. The performance of
post-biopsy MRI in the staging and detection of PCa is
significantly degraded by post-biopsy artefact [5, 6].
Therefore, it is recommended that MRI should be per-
formed at least 10 weeks after biopsy, and if possible
after 20 weeks [7]. Such a wait is unacceptable to pa-
tients and causes breaching of time with respect to treat-
ment guidelines. Improving early detection of clinically
significant PCa would very likely save many lives by re-
fining the stratification of patients for optimising the
treatment of significant disease, whilst simultaneously
diminishing patient anxiety and morbidity through over-
diagnosis and overtreatment.
Objectives
The primary objective is to determine whether using
multiparametric MRI (mpMRI) can improve cancer de-
tection and the characterisation of PCa, and primary
outcome measurements include:
 Number of PCa cases detected by mpMRI when
compared to gold-standard prostatectomy
specimens
 Number of clinically significant cancers detected by
mpMRI when compared to gold-standard prostatec-
tomy specimens
The secondary objective is to assess whether MRI/US
fusion-guided biopsy can reduce the number of false-
negative biopsies, and key outcome measurements
include:
 Number of cancers detected in each randomised
group, namely the intervention group (TRUS and
MRI/US fusion-guided biopsy) vs. the standard of
care group (TRUS only biopsy)
 Number of clinically significant cancers detected in
each randomised group
Trial design
This is a prospective multicentre study of pre-biopsy
mpMRI diagnostic test accuracy with subgroup random-
isation at a 1:1 ratio with respect to TRUS and MRI/US
fusion-guided biopsy or TRUS-only biopsy. This is the
first large trial to randomise men into either targeted or
non-targeted biopsy with pre-biopsy MRI and to choose
radical prostatectomy histopathology using 3D fabricated
moulds as the gold standard (Fig. 1).
Methods/design
Study population and setting
Prospective recruitment of men referred with suspected
clinically localised PCa will be carried out in urology
clinics. The number of patients screened for eligibility
over the recruitment period is estimated to be 1000. The
number of patients not eligible for the study is estimated
to be 350 and the number of patients who are likely to
decline is estimated to be 50. The number of partici-
pants who are likely to progress to pre-biopsy MRI is es-
timated to be 600. Local audit information suggests that
after a positive diagnosis of PCa, around 25% of men will
opt for radical surgery. Based on the recruitment of 600
eligible men, the lowest amount of complete data for
radical prostatectomy histology for analysis will be n =
~ 150. Our power calculation based on 80% sensitivity
and a precision of ± 9% and an AUROC = 0.9 suggests
that we need a minimum of 80 men with complete data-
sets from imaging and histopathology of radical prosta-
tectomy to answer the primary objective. The dropout
rate and incomplete datasets have been taken into con-
sideration in designing this study.
Rais-Bahrami et al. [8] suggest that 80% of all pre-
biopsy MRI scans (n = ~ 600) will have lesions suspi-
cious for PCa, regardless of the level of suspicion
assigned by mpMRI (n = ~ 480). Based on such informa-
tion, we calculated that each of the two randomisation
arms will have approximately 240 patients.
Initially, the total duration of the recruitment phase
was 48 months; however, this will now be extended to
66months with approval from the funding body. It is
estimated that approximately 600 participants will be
recruited and will receive a pre-biopsy MRI scan.
Participants will then be divided into two groups based
on the mpMRI results. The group with positive mpMRI
(n = ~ 480) will be randomised to the intervention
(TRUS and MRI/US fusion-guided biopsy) group (n = ~
240) or the standard care (TRUS-guided biopsy) group
(n = ~ 240). The group with negative mpMRI (n = ~
120) will undergo standard care (TRUS-guided biopsy)
with histological comparative analysis. Participants will
be followed through to a definite treatment stage. At
sites where local facilities allow and for those who will
undergo radical prostatectomy, histological findings will
be compared to the pre-biopsy MRI results (n = ~ 80).
The active trial participation for each participant will be
varied depending on sites’ local pathways.
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Participant selection and enrolment
As standard care pathways differ among sites, the route
of identification and screening of eligibility will differ in
order to accommodate the local pathway. Potential par-
ticipants will be identified by either the clinical team or
the study team, with Caldicott Guardian Approval, de-
pending on local practice.
Identifying potential participants
Potential participants may be identified through the fol-
lowing routes:
 At the urology clinic
 From GP referrals to the urology team
 By the urology team after standard care mpMRI
(positive results only)
Contacting potential participants
Contact will be made by either the clinical team or the
study team through the following routes:
 In person at clinics
The clinical team will assess whether the patient
meets the eligibility criteria for the study. If so, the
study patient information sheet (PIS) will be given
and a contact telephone number will be requested
for a follow-up telephone call. A model PIS is shown
in Additional file 1.
 Via letter
The clinical urological team will review GP referral
letters or positive mpMRI results and identify
patients who meet trial eligibility criteria. Those who
met the eligibility criteria will be sent a clinic
appointment with the trial information leaflet.
 Via telephone call
Fig. 1 Design of the trial
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The clinical urological team or delegate may contact
the patient and check whether he has received his
NHS clinic appointment before sending out the
information pack. After confirmation of receipt, the
urological team or delegate (with appropriate
Caldicott Guardian Approval) will introduce the
study to the patient, and if they indicate interest,
then an invitation pack will be sent.
If the patient declines the information pack or declines
to provide a telephone number, no further attempt to
recruit the patient will be made. The clinical or trial
team will telephone patients who have agreed to be con-
tacted. Any questions will be answered, and the patient
will be asked whether he is interested in participating.
The research team will arrange to see the patient for
consent discussion. If required, the patient will be given
additional time to consider participation before a final
decision is made to arrange an appointment.
Patients will be advised to attend all of their planned
scheduled appointments in the invitation letter and
study introduction call. Prospective participants will be
encouraged to telephone if they have any questions that
they would like answered prior to attendance or to in-
form the research team if they change their minds with
regard to participating. Patients who do not wish to par-
ticipate will follow their local standard of care pathway.
Inclusion criteria
 Males aged 40–75 years at referral
 Had an MRI scan within 3 months prior to
recruitment: for sites with pre-biopsy MRI included
in the standard of care
 With at least 10 years’ life expectancy at clinical
referral
 With clinically localised PCa: PSA ≤ 20 ng/ml
 And/or with abnormal DRE but < T3 disease
 Ability to give informed consent
Exclusion criteria
 Unable to give informed consent
 Prior prostatic biopsy within 12 months
 Contraindications to biopsy
 Poor general health and life expectancy < 10 years
 Previous diagnosis of acute prostatitis within 12
months
 History of PCa
 Prior transurethral prostatectomy
 Contraindications to MRI, including cardiac
pacemakers, allergic reaction to gadolinium-based
contrast, renal failure, intracranial clips,
claustrophobia (applicable to participants who do
not receive MRI as part of the standard care
pathway)
 Previous hip replacement
Ineligible and non-recruited participants
Ineligible patients or those who decide not to enter the
study will receive the standard of care. The reason(s) for
ineligibility will be explained to all individuals who express
interest in the study. Any questions they have will be an-
swered. A record of the number of patients screened will
be kept that indicates the number of patients eligible/ineli-
gible to participate.
Blinding
In this study, blinding of the biopsy performer on men
randomised to MR/US fusion-guided biopsy is not feas-
ible, but radiologists and pathologists will be double-
blinded regarding the patients’ outcomes until the end
of the statistical analyses.
Allocations and interventions
All enrolled participants will be offered 1.5 Tesla or 3.0
Tesla mpMRI prior to prostate biopsy where this is not
already within the standard care pathway. A subgroup of
participants with positive pre-biopsy MRI will be rando-
mised into two further subgroups at a 1:1 ratio.
Randomisation will be via TRUST, a web-based, good
clinical practice (GCP)-compliant randomisation system
run by the Health Informatics Centre (HIC). Randomisa-
tion will be implemented with random block sizes
stratified by site and minimised by: the Prostate Imaging
Reporting and Data System (PI-RADS) suspicion score
(3–5); index lesion size (in two categories: above and
below 6mm in maximal diameter on MRI); age (40–59
years, 60–75 years); and PSA < 10.1 or PSA ≥ 10.1 to ≤
20 ng/ml). The first subgroup will undergo a TRUS and
MRI/US fusion-guided biopsy and the second will
undergo standard of care TRUS-guide biopsies only. The
MRI/US fusion-guided biopsy will be performed during
the same attendance as the TRUS-guided biopsy. TRUS
and MRI/US fusion-guided biopsies will be performed
by NHS-accredited radiologists and/or urologists from
the research team. The persons undertaking the biopsy
will have prior experience and will have received
appropriate training from clinical experts and/or the
equipment supplier’s application specialist(s). Those par-
ticipants with negative pre-biopsy MRI will follow the
local standard of care pathway; where this includes bi-
opsy, data from the biopsy will be collected for analysis.
In a subgroup of patients who undergo radical prosta-
tectomy, the prostatectomy specimen will be sectioned
using customised moulds [9, 10] allowing for direct
comparison with mpMRI. This will be carried out in
Szewczyk-Bieda et al. Trials          (2019) 20:638 Page 4 of 8
NHS Tayside, NHS Grampian and other sites where
local facilities allow. Comparison of mpMRI with a refer-
ence standard of radical prostatectomy pathology will be
performed as the primary outcome.
Withdrawal procedures
It will be made clear to patients that they can withdraw
from the study at any time and return to the standard of
care. However, any data collected up to the time of with-
drawal will be included if participants agree to it.
Proposed outcome and statistical analyses
Prediction performance (Objective 1)
The diagnostic accuracy of each of the three mpMRI
predictive variables (T2WI (5-point ordinal scale), DWI
(5-point ordinal scale) and DCE-MRI (2-point ordinal
scale)) will be evaluated through logistic regression with
PCa as the binary outcome (Yes/No). The
T2WI and DWI will be dichotomised by assigning 0 to
scores of 1–2 and assigning 1 to scores of 3–5 [11], and
presented as percentages and denominators in the tables.
The predictive performance of the dichotomised
variables for the diagnosis of PCa will be analysed both
individually and by considering all possible combinations
among them. Additional variables as potential predictors
in the logistic regression model will also include age,
stage and comorbidity. Predictive ability will be esti-
mated from the area under receiver operating character-
istic (AUROC) curves drawn from the estimated
probabilities given by the corresponding logistic regres-
sion models. Accuracy will be assessed by implementing
the Hosmer–Lemeshow test for calibration. A score al-
gorithm will be derived from the final logistic regression
model.
Randomised controlled trial (Objective 2)
Analysis of the randomised comparison between MRI/
US fusion-guided biopsy and standard TRUS-guided bi-
opsy will be implemented according to the ICH E9 “Stat-
istical Principles in Clinical Trials”. Analysis will be
based on the intention-to-treat principle. The key out-
come for the randomised study is to measure whether
the MRI/US fusion-guided biopsy can improve the de-
tection of cancer foci and to establish the reliability of
the pre-biopsy MRI for the localisation of cancer foci
within the prostate gland.
Secondary outcomes will include the following:
 PCa detected on fusion biopsy which is missed on
TRUS biopsy
 Safety outcomes of death, and side effects such as
pain and bleeding with the severity and duration of
symptoms recorded in each randomised group
 Comparison of MRI-negative standard of care
TRUS-guided biopsies with MRI-positive TRUS
histopathology to facilitate analysis of the diagnostic
accuracy of MRI in men suspected of a target
condition
Binary outcomes such as cancer (Yes/No) and pain
(Yes/No) will be analysed using logistic regression with
the intervention arm as a binary variable in the model.
All analyses will be stratified by site and minimisation
variables, and adjusted for prostatic volume and max-
imum lesion size. Outcomes such as the Gleason Score
(GS) and the number of lesions (depending on the range
of values obtained) will be analysed as continuous linear
regression or ordinal logistic regression. Subgroup ana-
lyses will be carried out as secondary analyses by adding
treatment by subgroup variable interaction terms in the
regression model. Analyses will be conducted by the
study statisticians utilising SAS (9.4).
Data collection and management
The case report form (CRF) will be developed together
with the trial management team, statistician and data
manager to ensure that the data management system
supports the research aims of the study. The data man-
agement system will be fully validated, including the
provision of test data and supporting documentation. It
is the CI’s responsibility to ensure the accuracy of all
data entered and recorded in the CRF/Electronic Data
Capture System (EDCS). Data will be stored on servers
controlled by the HIC and housed at the University of
Dundee. Back-up and disaster recovery will be provided
by the HIC according to its standard operating proce-
dures. The data in the CRF will be stored by the MUL-
TIPROS study group for 5 years after the end of study.
Future information on the EDCS is available upon re-
quest to the HIC.
Trial management, monitoring and auditing
Study management
Tayside Clinical Trial Unit, a UKCRC-registered trials
unit, will be responsible for overseeing management of
the study. A dedicated trial-specific manager will run the
day-to-day work of the study and report to the CI.
Specifically, the trial manager, in consultation and close
working with the CI, will ensure the completeness and
consistency of CRFs. The study management team will
discuss any query and resolve it with input from the CI.
The CI may choose to delegate some of the tasks to a
member. A detailed trial-specific Delegation Log will be
made available at each recruiting site, with clear mention
of the tasks each member of staff will be taking part in.
The trial management group (TMG) consists of the
Chief and co-investigators and representatives from each
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participating site. The TMG meets monthly to keep
track of progress with recruitment and resolve chal-
lenges as and when they arise.
Joint Data Monitoring Committee and Trial Steering Group
Charter
A Trial Steering Committee (TSC) with an integrated
Data Monitoring Committee (DMC) will be put in place.
The combined group will perform a patient safety review
and provide overall strategic direction and supervision
during the progress of the study. The DMC is integrated
because the foreseen risk profile of the study is minimal.
Membership will consist of a lay-member of the patients
group as Chair and a minimum of two other experts in
the area of trial management or treatment of PCa. The
CI will participate as invited by the TSC/DMC. The in-
dependent committee members will ensure research
governance, review data and suggest alterations to the
study based on risk–benefit analyses of the data. The
later may include early termination of recruitment and
other modifications as desired. The terms of reference
will be agreed upon to clarify the membership, roles and
responsibilities of the joint committee. All of the pro-
cesses and procedures will be documented in the MUL-
TIPROS Joint Committee Charter.
Inspection of records
The CI, PIs and all of the participating sites for recruit-
ment in the study will undertake a commitment to allow
free study-specific monitoring, periodic audits and a
Research Ethics Committee (REC) review. It is expected
that the CI will sign an agreement to allow direct access
to all documentation and study-related records and ma-
terial for the study Sponsor or a representative of the
Sponsor whenever needed.
End of study
The end of study for a participant is the date at which
the biopsy procedure was performed plus 30 days. The
definition of the end of the study date for this trial is
database locked. The Sponsor, CI and/or management
group reserve the right to close the study to recruitment
for any reasons including safety of the participants, less
than satisfactory infrastructure or lack of progress. If the
decision is taken to terminate the study prematurely, the
decision on the end of the study will be communicated
to the Sponsor and REC within 90 days, or 15 days of
the decision. The CI will be responsible for any further
follow-up of the participants and their safety. The Spon-
sor and REC will be informed and a summary report of
the study will be submitted to both within 1 year of the
decision to end the study.
Harms
As the study does not employ an investigational medi-
cinal product, adverse events (AEs) and serious adverse
events (SAEs) will be recorded and reported as per the
Health Research Authority (HRA).
An SAE is defined as an untoward occurrence that:
 Results in death
 Is life-threatening
 Requires hospitalisation or prolongation of existing
hospitalisation
 Results in persistent or significant disability or
incapacity
 Consists of a congenital anomaly or birth defect
 Is otherwise considered medically significant by the
investigator
An SAE occurring for a research participant will be
reported to the main REC and Sponsor where, in the
opinion of the CI, the event is: related, it results from
administration of any of the research procedures; and
unexpected, the type of event is not listed in the proto-
col as an expected occurrence.
Due to the clinical status of the study population we
will record in the CRF, but not report to the REC or
Sponsor, SAEs in the following categories:
 Any death or hospitalisation due to new diagnosis or
treatment of a cancer
 Any death or hospitalisation due to exacerbation of
an existing medical condition
 SAEs due to expected side effects of biopsy as
defined in the BAUS “Transrectal Ultrasound-
Guided Biopsies of the Prostate Gland” leaflet
AEs will only be recorded in relation to study proce-
dures, namely, MRI, biopsy procedure and post-biopsy
events. Participants will either be called or approached
at the time of their routine clinic visit approximately 1–
2 weeks following the biopsy procedure to record
biopsy-related AEs. It is anticipated that pain and bleed-
ing will occur as a result of biopsy, but they will only be
recorded as an AE if they continue for more than 4 days
post biopsy.
Patient and public involvement
The research question was discussed in a Tayside
Urological Cancers Network (TUCAN) meeting with
input from patients and public representation. The main
attractions of the proposal for patients and the public
were reducing the number of biopsies, improving detec-
tion of clinically significant cancers and avoiding having
biopsies in men not needed. Patients helped in the prep-
aration of a layman summary during the grant
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application. They contributed to the design of informa-
tion and consent forms. We have advertised the study
locally in meetings with the patients and public such as
the Dundee Prostate Cancer Group and the Perth and
Kinross prostate cancer and prostate diseases groups.
The results will be summarised in a layman summary
(briefing document) and widely publicised in local and
national patients’ groups and prostate cancer charities.
The advantages of the intervention were discussed in pa-
tients’ and public engagement meetings.
Discussion
Study conduct responsibilities
Protocol amendments, deviations and breaches
It is expected that the study protocol and other docu-
mentation may need further amendments during the
lifetime of the proposed research. The CI will have a re-
sponsibility to inform and seek approval for any such
proposed alterations to the protocol from the Sponsor,
REC and NHS R&D Office(s). The changes thought to
be necessary in the study protocol will not be executed
without prior approval in place. The current protocol
version is V10.0 issued on 24 January 2019.
It will be the responsibility of the CI to ensure docu-
mentation of any deviation from the protocol that may
take place during the conduct of the trial. In case there
is any deviation necessary, a clear reason for and the na-
ture of this should be documented and communicated
to the Sponsor. In case deviation merits an amendment
in the study protocol, documentations need further sub-
mission to the Sponsor for approval and further appro-
priate action by the REC and NHS R&D Office to allow
necessary reviews and approval.
Any serious breach of GCP during the study, if sus-
pected, will be immediately reported to the Sponsor
using the standard form “Notification to Sponsor of
Serious Breach or Serious Deviation”.
Study record retention
Most of the source data within the study will form part
of the patient’s clinical records. Data generated specific-
ally for the study but of potential clinical relevance will
be stored in the patient records and are thus subject to
NHS Scotland minimum retention periods. In accord-
ance with this, pathology and genetic data and samples
will be kept for a minimum period of 30 years.
The research database which will bring together all
relevant data, and which will not contain personal iden-
tifiers, will be kept for a period of 5 years after the end
of the study. Records will then be deleted unless a review
at the time suggests that a longer retention period is in-
dicated. Access and security arrangements for the data-
base will be the same as those during the study.
Consenting participants
Timing of consent will differ depending on the local
standard care pathway; however, at all sites, consent will
be obtained prior to any study-related procedures com-
mencing. Patient consent will be discussed with a suit-
ably qualified member of the research team. Consent
will only be taken if patients express a wish to partici-
pate. Consent will only be sought once a full discussion
has taken place and the patient has expressed satisfac-
tion with the information received. The person discuss-
ing the study with the patient will normally be the
research nurse from the study team. A model consent
form is shown in Additional file 2.
Data access and confidentiality
The study team and the CI of the proposed trial will
ensure compliance to the requirement of the Data
Protection Act 1998. The core principles of the act such
as the collection, processing of information, disclosure
and long-term storage will be adhered to without excep-
tions. Given that the study involves a close collaboration
with the NHS, the CI and study team will ensure adher-
ence to the latest version of the NHS Scotland code of
practice and procedures on patient confidentiality.
Standard operating procedures such as limited access
measures to computers via confidential log-in and pass-
word details will be followed to ensure restricted access
to participant data by the CI. No personal data will be
published through outcomes of the study, and the par-
ticipants’ confidentiality will be ensured by not revealing
any identification details of the individuals.
Participants’ identifiable details through imaging data,
laboratory specimens, data entry forms, pathology reports
and other records will be protected through institutional
designed mechanisms. There will be access, on a principle
of “limitation of purpose“ basis, to all records for study
staff. Without prior written permission of the participants,
no clinical details except when absolutely necessary for
the purpose of study monitoring or auditing by the Spon-
sor will be disclosed or released by the CI or study team.
The Sponsor or its representative will be informed in writ-
ing to obtain permission of any disclosure to third party,
and without approval of the Sponsor no study confidential
data, records of the participants or any other unpublished
details will be disclosed.
Ancillary and post-trial care
After the biopsy procedure, the clinical/research team
will assess and record any experience of pain, haema-
turia and blood from the back passage. All criteria will
be assessed during a telephone call or clinic visit ap-
proximately 7–14 days post biopsy. Patients will be given
a diary sheet as an aide-mémoire to record any symp-
toms which will be used to complete the CRF via
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telephone call/clinic visit. In the event that a diary sheet
is not completed/returned, the clinical/research team
will review the clinical records to assess whether the par-
ticipant has experienced any defined AEs and record this
in the CRF. A model patient biopsy diary form is shown
in Additional file 3.
Dissemination
The results of this study will be used for publication and
presentation in national and international journals and
at scientific conferences.
Roles and responsibilities
For roles and responsibilities of the trial sponsor, CI, PI
and committees in this study, please see Additional file
4. This study protocol follows the 2013 Standard Protocol
Items: Recommendations for Interventioanl Trials
(SPIRIT) statement and the SPIRIT checklist is shown in
Additional file 5.
Trial status
The favourable approval for this trial was obtained from
the East of Scotland REC 1 (Ref: 14/ES/1070) on 20
November 2014. The first patient was enrolled on 17 Feb-
ruary 2015, with 416 participants so far recruited. The
total duration of the recruitment phase was 48months;
however, this has now been extended to 66months. The
recruitment is scheduled to finish on 30 June 2020.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3746-0.
Additional file 1: Participant information sheet.
Additional file 2: MULTIPROS study, informed consent form.
Additional file 3: Patient’s biopsy diary.
Additional file 4: Roles and responsibilities.
Additional file 5: SPIRIT Checklist for this clinical trial.
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